Public Tender Offer Capio Laboratories AB, Gothenburg
Total Page:16
File Type:pdf, Size:1020Kb
THIS OFFER IS NOT BEING MADE AND THIS DOCUMENT MAY NOT BE DISTRIBUTED IN OR INTO THE UNITED STATES OF AMERICA, EITHER DIRECTLY OR INDIRECTLY. Public Tender Offer by Capio Laboratories AB, Gothenburg, Sweden (an indirect subsidiary of Capio TopHolding AB, Gothenburg, Sweden) for all publicly held Bearer shares with a nominal value of CHF 1 each Registered shares with a nominal value of CHF 0.50 each Shareholder options for bearer shares with a nominal value of CHF 1 each of Unilabs SA, Geneva Offer Price: CHF 57.50 net in cash for each bearer share of Unilabs SA with a nominal value of CHF 1 each, CHF 28.75 net in cash for each registered share of Unilabs SA with a nominal value of CHF 0.50 each, CHF 1.75 net in cash for each shareholder option for bearer shares of Unilabs SA with a nominal value of CHF 1 each, in each case reduced by the gross amount of any dilution effects (e.g., dividend payments and any other kind of distributions, capital increases with an issue price per share below the stock market price, issue of options with a strike price per share below the stock market price and capital repayments) per registered share, bearer share or shareholder option, to the extent that these dilution effects occur prior to the consummation of the offer. Offer Period: October 9, 2007 to November 5, 2007, 4:00 p.m. CET (subject to extension) Tender Agent: UBS AG Unilabs SA, Geneva Securities number ISIN Ticker symbol Bearer Shares 1256164 CH0012561640 ULB Bearer Shares (2nd trading line) 3419586 CH0034195864 ULBE Registered Shares 616527 CH0006165275 ULBN Shareholder Options for Bearer Shares 2343118 CH0023431189 ULBSA Shareholder Options for Bearer Shares (2nd trading line) 3419592 CH0034195922 ULBSAE Offer Prospectus dated October 9, 2007 Offer restrictions General This public tender offer (the Offer) to the public shareholders and the holders of options for bearer shares of Unilabs SA, Geneva (Unilabs), will not directly or indirectly be made in a country or a jurisdiction in which such Offer would be illegal or otherwise violate applicable law or regulations or which would require Capio Laboratories AB, Sweden (formerly Goldcup J 2653 AB, hereinafter Capio) or Capio TopHolding AB, Sweden (formerly Opica TopHolding AB, hereinafter Capio TopHolding) to change the terms or conditions of the Offer in any way, to submit an additional application or to perform additional actions in relation to any state, regulatory or legal authorities. It is not intended to extend the Offer to any such country or such jurisdiction or to persons in such country or jurisdiction. Documents relating to the Offer must neither be directly or indirectly distributed in such countries or jurisdictions nor be sent to such countries or jurisdictions. Such documents must not be used for the purpose of soliciting the purchase of securities of Unilabs by anyone from such countries or jurisdictions. Persons in possession of this offer prospectus (the Offer Prospectus) or any other document relating to the Offer are required to obtain information about any local restriction that may apply and comply therewith. Capio and Capio TopHolding decline any liability for any violation of any applicable restrictions by any person. United States of America The Offer is not being made, directly or indirectly, in or into the United States of America (the U.S.) or by use of the U.S. mails, or by any means or instrumentality (including, without limitation, post, facsimile transmission, telex, telephone or electronic transmission by way of the internet or otherwise) of U.S. interstate or foreign commerce or of any facility of a U.S. national securities exchange and the Offer cannot be accepted by any such use, means or instrumentality or from within the U.S. Capio and Capio TopHolding are not soliciting the tender of securities of Unilabs by any holder of such securities in the U.S. Unilabs securities will not be accepted from holders of such securities in the U.S. Any purported acceptance of the Offer that Capio and Capio TopHolding or their agents believe has been made in or from the U.S. will be invalidated. Capio and Capio TopHolding reserve the absolute right to reject any and all acceptances determined by them not to be in the proper form or the acceptance of which may be unlawful. Copies of this Offer Prospectus or any related offering documents must not be mailed or otherwise distributed or sent in or into the U.S. and may not be used for the purpose of soliciting the purchase of any securities of Unilabs from anyone in any jurisdiction, including the U.S., in which such solicitation is not authorized or from any person to whom it is unlaw- ful to make such solicitation. Any person receiving this Offer Prospectus (including custodians, nominees and trustees) must observe these restrictions. 2 A. Background of the Offer As of August 6, 2007, Capio Laboratories AB, Sweden (formerly Goldcup J 2653 AB, hereinafter Capio) entered into a Share Purchase Agreement (SPA) with the majority shareholders of Unilabs, being Edgard Zwirn, Gibraltar; Forbes Associates Limited, BVI; Rockaway International Limited, BVI; Charminster Trading Ltd., BVI; Hanway Investment Ltd., BVI; Lakebuild Invest Limited, United Kingdom; Winterland Assets Limited, BVI; Lancaster Enterprises Inc., BVI; Felice Holdings S.A., BVI; Alexe Technologies Limited, BVI; Zadax & Cie SA, Switzerland; Zadax Funds PCC Limited, Gibraltar; Helvetica Invest Limited, Gibraltar; Winspade Holdings Limited, BVI; and Alante Investments Corp., República de Panamá (hereinafter collectively referred to as the Majority Shareholders), which governs the purchase of 4,799,690 Unilabs registered shares, 1,410,184 Unilabs bearer shares, 4,800,000 shareholder options for Unilabs registered shares and 926,762 shareholder options for Unilabs bearer shares (the registered and bearer shares and the options in Unilabs purchased under the SPA hereinafter referred to as the SPA Securities). Capio published the pre-announcement of this Offer electronically on August 7, 2007 and by publication in newspapers on August 9, 2007 in accordance with art. 7 et seq. of the Ordinance of the Takeover Board on Public Takeover Offers (TOO). In its recommendation dated August 22, 2007, the Swiss Takeover Board concluded that the purchase and sale of the SPA Securities under the SPA qualify as prior acquisition according to art. 32 (4) Federal Act on Stock Exchanges and Securities Trading (SESTA) and art. 38 Ordinance of the Federal Banking Commission on Stock Exchanges and Securities Trading (SESTO-FBC) with the effect that the acquisition of the SPA Securities under the SPA is not subject to the best price rule. Closing of the SPA took place on October 4, 2007. The shares acquired under the SPA are equivalent to 38.10% of the Unilabs share capital or 50.08% of the Unilabs voting rights. As agreed in the SPA, on the closing date Mr. Edgard Zwirn resigned as member and chairman of the board of directors and as chief executive officer of Unilabs, and Mrs. Alessandra Gherardi resigned as member of the board of directors of Unilabs. Under the SPA, the Majority Shareholders agreed to pub- licly support and recommend the Offer. With the closing of the SPA, this undertaking was fulfilled and the Majority Shareholders have no more obligations with respect to this Offer. 1 With the closing of the SPA, Capio exceeded the threshold of 33 /3 % of voting rights under the terms of Art. 32 (1) SESTA and Capio is obligated pursuant to this provision to make a public tender offer for all publicly held listed securities of Unilabs. B. The Offer 1. Pre-Announcement Capio published the pre-announcement of this Offer by transmission to the electronic media on August 7, 2007 and by publication in the “Neue Zürcher Zeitung” and “Le Temps” on August 9, 2007 in accordance with art. 7 et seq. TOO. The conditions precendent for this Offer set forth in the pre-announcement have been fullfilled. 2. Scope of the Offer The Offer is made for all publicly held • bearer shares of Unilabs with a nominal value of CHF 1 each (the Bearer Shares); • registered shares of Unilabs with a nominal value of CHF 0.50 each (the Registered Shares); and • shareholder options for bearer shares of Unilabs with a nominal value of CHF 1 each (the Bearer Options); (the Bearer Shares, Registered Shares and the Bearer Options collectively the Unilabs Securities) including all Registered Shares and Bearer Shares issued until the end of the additional acceptance period, utilizing the conditional or authorized share capital of Unilabs. This Offer is not made for Unilabs Securities held by Capio or its affiliates at the time of this Offer, including those Unilabs Securities held by Unilabs and its subsidiaries. The number of Unilabs Securities included in the Offer as of October 4, 2007 (close of stock exchange) is calculated as follows: 3 Existing Bearer Shares issued Bearer Shares as of October 4, 2007 7,600,000 minus Bearer Shares directly or indirectly held by Capio and (pre-existing) Capio affiliates as of October 4, 2007 (2,577,310) minus Bearer Shares held by Unilabs and its subsidiaries as of October 4, 2007 (621,136) = existing Bearer Shares included in the Offer 4,401,554* Bearer Shares to be issued plus the maximum number of Bearer Shares which could be issued until the end of the additional acceptance period utilizing the conditional or authorized capital of Unilabs (cf. Section E.2) 2,264,000 = maximum number of Bearer Shares included in the Offer 6,665,554 Existing Registered Shares issued Registered Shares as of October 4, 2007 4,800,000 minus Registered Shares directly or indirectly held by Capio and (pre-existing) Capio affiliates as of October 4, 2007 (4,799,690) minus Registered Shares held by Unilabs and its subsidiaries as of October 4, 2007 0 = existing Registered Shares included in the Offer 310* Registered Shares to be issued plus the maximum number of Registered Shares which could be issued until the end of the additional acceptance period utilizing the conditional or authorized capital of Unilabs (cf.